Program
BCMA-CD19 Compound CAR T Cells
Its studies are mostly in Multiple Myeloma · Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic, led by iCell Gene Therapeutics.
Furthest: phase 1, since Nov 11, 20193 company-led studies, 3 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| iCell Gene Therapeutics | 33 open or running | phase 1since Nov 11, 2019 | Nov 11, 2019 | none ahead |
Also a collaborator on its studies: iCAR Bio Therapeutics and iCell ImmunityX(Hangzhou).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2019First study: phase 1 study in Multiple MyelomaFirst studyNCT04162353 · 12 planned · China
- Jul 23, 2022Phase 1 study in RecurrenceNCT05474885 · 15 planned · China
- Jan 8, 2025Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT06787989 · 20 planned · China
TargetBeta
“A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06787989Purpura, Thrombocytopenic, Idiopathic · China | 1 | Recruiting | Aug 2026 | 20 |
| NCT05474885Recurrence · China | 1 | Recruiting | Apr 30, 2025 | 15 |
| NCT04162353Multiple Myeloma · China | 1 | Recruiting | Jul 2026 | 12 |
How it is read
Names in the registry
- “BCMA-CD19 cCAR T cells”, 3 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.